News Search Results
Mar 24, 2026, 08:00 ET Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Mar 24, 2026, 08:00 ET Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
durable cell-based therapies for T1D a clinical reality.About Continuity BiosciencesContinuity Biosciences is a clinical-stage biotechnology company developing implantable and device-enabled platform technologies at the intersection of drug delivery, biologics, and medical devices. The
More news about: Continuity Biosciences LLC
Mar 24, 2026, 08:00 ET Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
durable cell-based therapies for T1D a clinical reality.About Continuity BiosciencesContinuity Biosciences is a clinical-stage biotechnology company developing implantable and device-enabled platform technologies at the intersection of drug delivery, biologics, and medical devices. The
More news about: Continuity Biosciences LLC
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
resourcesSAN DIEGO, March 24, 2026 /PRNewswire/ -- RyboDyn, Inc., a biotechnology company decoding the dark proteome using an AI-powered novel sequencing and discovery platform, today announced the initial close of a $10M Seed
More news about: RyboDyn
Mar 24, 2026, 07:55 ET EpiFrontier Therapeutics Secures up to $32M Grant from the Japan Agency for Medical Research and Development to Advance Novel Therapy for Beta Globin Disorders
N.J. and TOKYO, March 24, 2026 /PRNewswire/ -- EpiFrontier Therapeutics, Inc., a biotechnology company developing transformative therapies for beta globin disorders, today announced its award of up to $32 million in non-dilutive funding from
More news about: EpiFrontier Therapeutics
Mar 24, 2026, 07:30 ET Origin Agritech Names Global Crop Biotechnology Expert Dr. Jian Zhang to Board of Directors; Welcomes Return of Dr. Z. James Chen as Chief Financial Officer
product series as well as Senior Manager of GMO Regulatory and Biotechnology Affairs for China and Asia-Pacific region; and as Global Head of Quality Control for biotech crops at BASF Plant Science. He holds extensive expertise in crop biotechnology R&D, regulatory safety assessment, and biotech compliance
More news about: Origin Agritech
Mar 24, 2026, 07:30 ET Architect of Modern Diabetes Medicine Dr. Ralph A. DeFronzo Joins Pramana Pharmaceuticals as Chief Medical Advisor
Pramana Pharmaceuticals Inc., a biotechnology company developing a first in class oral treatment to restore systemic metabolic resilience, today announced that internationally renowned physician-scientist Dr.
More news about: Pramana Pharmaceuticals Inc.
Mar 24, 2026, 06:29 ET Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
aligned goals to advance innovation in women's health.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Mar 24, 2026, 06:06 ET Technology Dashboard 2025: U.S. remains leading country of origin for European patent applications as China makes gains
This was the fastest-growing of the leading fields overall the EPO in 2025, driven by the global race to develop 6G technologies.Biotechnology: with 2,779 applications, saw a notable decrease (-9.0%).Pharmaceuticals: with 2,772 applications, also posted a drop (-10.3%).U.S.
More news about: European Patent Office (EPO)
Mar 24, 2026, 04:45 ET IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel
More news about: IASO Bio
Mar 24, 2026, 03:43 ET DualityBio (9606.HK) Announces 2025 Annual Results
enterprise and provide therapeutic options for patients worldwide.About DualityBioDualityBio (HKEX:09606) is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation antibody-drug conjugates to treat cancer and autoimmune diseases.DualityBio
More news about: Duality Biotherapeutics, Inc.
Mar 23, 2026, 12:07 ET Cambridge Innovation Institute Announces Acquisition of Neurotech Reports
to the field and future developments. Through their brands, Neurotech Reports connects entrepreneurs interested in launching new firms, existing biotechnology and medical device manufacturers interested in branching into a new market, scientific and engineering professionals interested in applying their
More news about: Cambridge Innovation Institute
Mar 23, 2026, 09:55 ET Integral Molecular Appoints Cheryl Paes as Vice President of Commercial Strategy
In this role, Paes will lead strategic initiatives to support the continued commercial growth of the company's technology platforms to serve the biotechnology and pharmaceutical industries.
More news about: Integral Molecular
Mar 23, 2026, 08:34 ET GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a collaboration agreement
More news about: GlycoNex, Inc.
Mar 23, 2026, 08:30 ET Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
60 to 200 molecules synthesized and tested in each program.About Insilico MedicineInsilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life
More news about: Insilico Medicine
Mar 23, 2026, 08:00 ET Stealth BioTherapeutics Announces MRC Business Engagement Fund Grant to Advance Mitochondrial Disease Research
England, March 23, 2026 /PRNewswire/ -- Stealth BioTherapeutics (the "Company"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced
More news about: Stealth BioTherapeutics Inc.
Mar 23, 2026, 07:45 ET Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
designations, and led clinical diligence teams for numerous oncology business development opportunities culminating in Janssen's acquisitions of Cougar Biotechnology, Aragon Pharmaceuticals, and TARIS Biomedical along with Janssen's co-development agreements with Legend Biotech, Pharmacyclics/AbbVie, Tesaro/GSK,
More news about: TuHURA Biosciences, Inc.
Mar 23, 2026, 07:30 ET HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: Soligenix
Mar 23, 2026, 07:01 ET Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases
SAN MATEO, Calif., March 23, 2026 /PRNewswire/ -- Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with
More news about: Kali Therapeutics
Mar 23, 2026, 07:00 ET Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Mar 23, 2026, 02:29 ET Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector.""We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical
More news about: ClinChoice Inc
Mar 23, 2026, 02:10 ET Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector.""We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical
More news about: ClinChoice Inc
Mar 22, 2026, 23:14 ET Harbour BioMed Reports the Online Publication of Phase I Results for HBM9378 (SKB378/WIN378), a TSLP-Targeting Antibody
multiple ADC and novel DC assets in clinical or preclinical research stage.About Windward Bio AGWindward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced
More news about: Harbour BioMed
Mar 21, 2026, 12:42 ET Sind hochwertige Proteine kein Luxus mehr? Auf der FIC 2026 zeigt Angel Yeast neue Wege auf
um einen Konsens zu erzielen und den Wissensaustausch zu fördern. Im Bereich der Produktion hat Angel Yeast im vergangenen November im Baiyang Biotechnology Park in Yichang eine neue Produktionslinie für Hefeproteine in Betrieb genommen, wodurch die jährliche Produktionskapazität um mehr als 10.000 Tonnen
More news about: Angel Yeast
Mar 21, 2026, 11:38 ET 고품질 단백질, 더 이상 사치품이 아니다? 엔젤 이스트, FIC 2026에서 그 방법을 제시하다
Symposium on Yeast Protein Science and Technology)을 개최하고, 산업 백서를 발표해 공감대를 형성하고 지식 공유를 촉진할 계획이다. 생산 측면에서는 지난해 11월 이창 바이양 생명공학 단지(Yichang Baiyang Biotechnology Park)에 신규 효모 단백질 생산라인을 가동하며 연간 1만 톤 이상의 생산능력을 추가했다. 급증하는 시장 수요에 대응하기 위해 엔젤 이스트는 이미 추가 증설도 계획하고 있으며, 이를 통해 공급 역량을 강화할 방침이다.엔젤 이스트는 시장 개발 측면에서도
More news about: Angel Yeast